PMID- 29384691
OWN - NLM
STAT- MEDLINE
DCOM- 20190208
LR  - 20190215
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 142
IP  - 5
DP  - 2018 May
TI  - Utility of Alternate, Noncentromeric Chromosome 17 Reference Probe for Human 
      Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Testing in 
      Breast Cancer Cases.
PG  - 626-633
LID - 10.5858/arpa.2017-0252-OA [doi]
AB  - Context PathVysion-a US Food and Drug Administration-approved dual-probe human 
      epidermal growth factor receptor ( HER2) fluorescence in situ hybridization 
      (FISH) assay-provides the HER2: CEP17 ratio, a centromeric enumeration probe 
      ratio for determining HER2 status in breast cancers. However, pericentromeric 
      amplifications might then skew the HER2: CEP17 ratio, underestimating the HER2 
      status, which calls into question the use of CEP17 as the reference probe. 
      Objective To analyze the utility of a noncentromeric chromosome 17 reference 
      locus ( D17S122) to assess HER2 gene status in cases showing "nonclassical" FISH 
      patterns with the CEP17 probe. Design The HER2 status of breast cancers 
      accessioned in the years 2015-2017, displaying "nonclassical" or "equivocal" 
      results by the PathVysion (Abbott Molecular Inc, Des Plaines, Illinois) HER2 DNA 
      Probe Kit were reflex tested using an alternate FISH probe (ZytoLight 
      SPEC/D17S122, ZytoVision, Bremerhaven, Germany) and interpreted with American 
      Society of Clinical Oncology/College of American Pathologists 2013 guidelines. 
      Results Of 37 cases, 17 were FISH equivocal. With the alternate D17S122 probe, 13 
      (76.4%) were reclassified as amplified, 3 (17.6%) as nonamplified, and a single 
      case retained an equivocal result. Of the 17 cases with a chromosome 17 polysomy 
      pattern, disomy, polysomy, and monosomy patterns were seen with 14 cases, 2 
      cases, and 1 case, respectively. Within the 17 cases with polysomy pattern, 3 
      (17.6%) demonstrated an unusual colocalization pattern of HER2 and CEP17, which 
      was not observed with the alternate probe. Conclusions The denominator-stable 
      alternate probe is a useful adjunct in the diagnostic armamentarium to analyze 
      HER2 status in cases with FISH equivocal and complex patterns.
FAU - Pai, Trupti
AU  - Pai T
FAU - Shet, Tanuja
AU  - Shet T
FAU - Patil, Asawari
AU  - Patil A
FAU - Shetty, Omshree
AU  - Shetty O
FAU - Singh, Angad
AU  - Singh A
FAU - Desai, Sangeeta B
AU  - Desai SB
AD  - From the Division of Molecular Pathology (Drs Pai, Shetty, Singh, and Desai) and 
      the Department of Pathology (Drs Pai, Shet, Patil, Shetty, Singh, and Desai), 
      Tata Memorial Centre, Mumbai, India.
LA  - eng
PT  - Journal Article
DEP - 20180131
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Breast Neoplasms/*genetics
MH  - *Chromosomes, Human, Pair 17
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/*genetics
EDAT- 2018/02/01 06:00
MHDA- 2019/02/09 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2019/02/09 06:00 [medline]
PHST- 2018/02/01 06:00 [entrez]
AID - 10.5858/arpa.2017-0252-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2018 May;142(5):626-633. doi: 10.5858/arpa.2017-0252-OA. 
      Epub 2018 Jan 31.